Tổn thương thần kinh ngoại vi ở bệnh nhân hóa trị phác đồ có oxaliplatin

Abstract

Objective: To identify peripheral neuropathy in oxaliplatin-based adjuvant chemotherapy patients. Subject and method: Retrospective study on 151 gastric and colon cancer patients treated with 6-month adjuvant chemotherapy regimens with XELOX, mFOLFOX6 at the Department of General Oncology - 108 Military Central Hospital. Result: The most common acute peripheral neuropathy was numbness of extremities when experiencing cold (64.4% in XELOX regimen and 65.4% in mFOLFOX6 regimen), numbness at the infusion site was more common in XELOX regimen (38.4% vs 15.4%; p=0.001); jaw pain was more common in XELOX regimen (20.5% vs 3.8%; p=0.002). Chronic peripheral neuropathy with numbness of the extremities increasing gradually with the cumulative dose of oxaliplatin (from 3.8% after cycle 1 to 74.4% after 12 cycles of mFOLFOX6 and from 2.7% after cycle 1 to 71, 2% after 8 cycles of XELOX) but mainly at grade 1, 2 and gradually decreased after stopping treatment (73.1% lasted for 24 months with XELOX regimen and 94.8% with mFOLFOX6 regimen). Conclusion: Peripheral neuropathy due to oxaliplatin includes acute cold-related injury, occurs during and immediately after infusion; and chronic toxicity increases gradually with cumulative dose but mainly grade 1, 2 and decreases after stopping treatment.